Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:developedBy |
gptkb:Arbutus_Biopharma
|
| gptkbp:effect |
reduces hepatitis B surface antigen (HBsAg)
|
| https://www.w3.org/2000/01/rdf-schema#label |
AB-729
|
| gptkbp:intendedUse |
treatment of chronic hepatitis B
|
| gptkbp:mechanismOfAction |
gptkb:RNA_interference
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:status |
investigational drug
|
| gptkbp:synonym |
AB729
|
| gptkbp:target |
HBV mRNA
|
| gptkbp:bfsParent |
gptkb:Arbutus_Biopharma
|
| gptkbp:bfsLayer |
7
|